Five Prime Therapeutics (NASDAQ:FPRX) Moves On Wedbush Initiation. How Much Are Shares Worth?

May 18, 2018 - By Hazel Jackson

Investors sentiment increased to 1.34 in Q4 2017. Its up 0.30, from 1.04 in 2017Q3. It improved, as 21 investors sold Five Prime Therapeutics, Inc. shares while 29 reduced holdings. 24 funds opened positions while 43 raised stakes. 25.47 million shares or 6.30% more from 23.96 million shares in 2017Q3 were reported.

Morgan Stanley owns 0% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for 351,666 shares. Guggenheim Capital accumulated 58,501 shares. Ameriprise invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Goldman Sachs Grp reported 153,300 shares or 0% of all its holdings. Franklin Street Advisors Nc, North Carolina-based fund reported 25,000 shares. Bnp Paribas Arbitrage Sa has 5,650 shares. Wellington Mngmt Group Incorporated Llp owns 0.01% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for 2.98 million shares. Barclays Public Ltd Liability invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Mufg Americas Holdg Corporation has invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Tudor Invest Et Al has invested 0.01% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Moreover, Bancorporation Of Montreal Can has 0% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Prelude Capital Ltd Company accumulated 139 shares. Ny State Common Retirement Fund holds 0% or 30,600 shares in its portfolio. Tower Research Cap Ltd (Trc) has 1,744 shares. Granite Point Cap L P holds 80,000 shares or 0.17% of its portfolio.

Why Has Wedbush Given Five Prime Therapeutics (NASDAQ:FPRX) a $17.0000 Price Target

In analysts report revealed to clients and investors today, Wedbush analysts began Five Prime Therapeutics (NASDAQ:FPRX) coverage with Hold rating, and a $17.0000 PT.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Ratings Coverage

Among 5 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Five Prime Therapeutics has $60 highest and $20 lowest target. $35’s average target is 90.74% above currents $18.35 stock price. Five Prime Therapeutics had 5 analyst reports since February 15, 2018 according to SRatingsIntel. Guggenheim maintained the shares of FPRX in report on Thursday, February 15 with “Buy” rating. The firm earned “Buy” rating on Thursday, March 1 by Jefferies. The firm earned “Buy” rating on Wednesday, February 28 by Nomura. The firm earned “Outperform” rating on Wednesday, February 28 by BMO Capital Markets.

The stock decreased 2.91% or $0.55 during the last trading session, reaching $18.35. About 52,605 shares traded. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has declined 52.34% since May 18, 2017 and is downtrending. It has underperformed by 63.89% the S&P500.

Analysts await Five Prime Therapeutics, Inc. (NASDAQ:FPRX) to report earnings on August, 14. They expect $-1.33 EPS, up 15.82 % or $0.25 from last year’s $-1.58 per share. After $-0.63 actual EPS reported by Five Prime Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 111.11 % negative EPS growth.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the United States. The company has market cap of $646.09 million. The companyÂ’s product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. It currently has negative earnings. The Company’s product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors.

More recent Five Prime Therapeutics, Inc. (NASDAQ:FPRX) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on May 18, 2018. Also Seekingalpha.com published the news titled: “Five Prime Therapeutics’ (FPRX) CEO Aron Knickerbocker on Q1 2018 Results – Earnings Call Transcript” on May 13, 2018. Streetinsider.com‘s news article titled: “Goldman Sachs Starts Five Prime Therapeutics (FPRX) at Neutral” with publication date: May 10, 2018 was also an interesting one.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.